HealthTech company Advanced Health Intelligence (ASX: AHI) is set to launch a medically-approved mobile phone-based atrial fibrillation (AF) assessment in Q2 CY24 in collaboration with Belgium-based Qompium NV, a company specialising in mobile scanning tech.
Globally, there are about 60 million cases of atrial fibrillation (AF), which is a form of arrhythmia involving irregular heartbeat. Despite its prevalence, its detection remains tricky, seeing as about 40% of patients are asymptomatic. AF can have dire consequences, increasing the risk of stroke five-fold—making it crucial to have a better detection solution in place.
That’s where AHI’s new smartphone-based AF scan comes into play. The five-year agreement with Qompium NV expands its current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service. AHI will pay Qompium an initial cash fee for the right to access the AF Scan software, with another cash fee payable following the completion of the integration.
Chief Innovation Officer at AHI, Dylan Garnett, said, “AF-Scan is a revolutionary addition to our Cardiac Health portfolio. This innovation comes at a critical time, as emerging research highlights novel AF risk factors, emphasising the importance of risk factor interventions in reducing AF incidence and managing episodes effectively.
“AF-Scan is a groundbreaking mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide.”
The AF scan uses Photoplethysmography (PPG) tech, which is non-invasive. A detector and light source on your skin detects subtle changes in blood vessels as your heart beats. This provides precise insights into your heart’s rhythm and overall health.
AHI’s BHA uses your smartphone’s flashlight and camera to gather PPG data. It employs a certified AI algorithm to swiftly analyse this data, generating a user-friendly report for your physician. This report helps you and your doctor discuss and make informed decisions about your heart health. In a nutshell, AF-Scan’s PPG tech lets you conveniently monitor your heart rhythm with your smartphone for timely healthcare decisions.
The application has been medically approved in Australia, USA, Singapore, EU, UK, UAE and Saudi Arabia for near clinical. The technology has received medical approval in multiple jurisdictions.
AF currently affects 2-4% of the population, with a rising trend due to an increasing ageing population and subsequent detection efforts. Aging is a significant risk factor, along with comorbidities like hypertension and diabetes. Globally, the AF market is projected to surpass $72.7 billion by 2030. Besides its health concerns, AF also weighs heavily on healthcare systems and economies, costing institutions plenty in detection and treatment.
AF Scan will assist in the screening identification dilemma of at-risk individuals, which is one of the most significant challenges associated with AF. The condition is notorious for being elusive and, at times, asymptomatic, making it challenging to identify in its early stages.
Founder and Head of Strategy at AHI, Vlado Bosanac, said, “AHI will incorporate the AF-Scan into our biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers.
“This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing us to offer a holistic view of their well-being.”
The Company did not mention potential revenue from this agreement.
- Auswide Bank sees NPAT decline by over 45% in the face of tough competition - February 26, 2024
- No discount? No deal: Value-oriented customers leave Adairs in the lurch - February 26, 2024
- Devastating storms and cancellations see Coast Entertainment’s earnings decline - February 23, 2024